Market Overview

EXCLUSIVE: Philidor Calls Short-Sellers 'Discredited' And 'Patently False'; Citron's Andrew Left Responds

EXCLUSIVE: Philidor Calls Short-Sellers 'Discredited' And 'Patently False'; Citron's Andrew Left Responds

Valeant Pharmaceuticals Intl Inc (NYSE: VRX) shares are relatively unchanged in Tuesday's after-hours session following a press release from Philidor. The specialty pharma company said it's "deeply disappointed" its working relationship with Valeant has ended, adding that it's unfortunate "market forces, media misperceptions, and inflammatory, patently false reports by discredited short-sellers" were responsible.

Philidor added it will continue to work closely with regulators to address outstanding inquiries.

In an exclusive call with Benzinga, Citron Research's Andrew Left -- who said the stock is worth $50 and asked "could this be the Pharmaceutical Enron?" in late October -- responded.

According to Left, the statement's mention of short-sellers shows where the company's focus has been over the past couple weeks. In other words, Philidor is focusing on exterior factors and not its own business.

A Philidor spokesperson had no comment on the release, and said the company will not conduct any media interviews in the immediate future.

Posted-In: Andrew Left CitronBiotech News Short Sellers Exclusives Movers General Best of Benzinga


Related Articles (VRX)

View Comments and Join the Discussion!
Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Daily Analyst Rating
A summary of each day’s top rating changes from sell-side analysts on the street.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at